Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis’ Q2 Net Sales Up 11.2%
Sanofi-aventis has reported an increase in net sales by 11.2% to E7.43 billion in the second quarter of 2009, as compared to the net sales of the prior
Sanofi-aventis has reported an increase in net sales by 11.2% to E7.43 billion in the second quarter of 2009, as compared to the net sales of the prior
Recordati has signed an exclusive license agreement with Pharmaplan for the marketing and sales of silodosin in South Africa. Silodosin is a new compound indicated for the treatment
GlaxoSmithKline (GSK) and Genmab have announced preliminary top-line results from a phase III study of ofatumumab, administered intravenously. The drug is for the treatment of rheumatoid arthritis (RA)
Evotec has reported that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim. The milestone was
Access is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis. In connection with the North American
Pfizer has signed a strategic partnership with the Shanghai Institutes for Biological Sciences (SIBS), to support fundamental research in China. The company said that the research projects will
FORMA has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein
Inovio’s SynCon H1N1 influenza DNA vaccines achieved protection against swine origin influenza A/H1N1 viruses in animal studies. The company had previously reported data from an ongoing study in
A new bill was introduced in the US legislature that proposes to overhaul the system for providing global development aid, reports Boston Globe. The bill, introduced on Tuesday,
Neurocrine has reported six month safety and efficacy results from its fourth phase II clinical trial – orally-active, non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix – in patients